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Figure 2 Box plot of mean positivity time for pathogens 
and contaminants (95% confidence band about median). 
a fall in the yield of organisms; in fact, this group had 
the largest number of clinically significant positive 
cultures. Our protocol, using as small a blood volume 
as 1 mL and a dilution factor of 1 :41, appears to be a 
valid choice to demonstrate bloodstream infection in 
patients under 34 months of age. 
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Activity of eight fluoroquinolones against enterococci 
Clin Microbiol Infect 1997; 3: 497-499 
The incidence of nosocomial infections caused by 
Enterococcus spp. has increased dramatically in recent 
years. In fact, Enterococcus spp. are currently among 
the leading causes of nosocomial infection [I]. The 
emergence of enterococci resistant to glycopeptides, 
the increase in high-level resistance of aminoglycosides, 
the production of P-lactamase by certain strains and 
the intrinsic resistance of enterococci to several anti- 
microbials serve to limit the therapeutic options for the 
treatment of infections caused by these microorganisms 
PI ' 
Commercially available fluoroquinolones are not 
very useful for the treatment of infections caused by 
enterococci [3]. In recent years, new fluoroquinolones 
have been developed offering a broader spectrum 
and higher activity against Gram-positive cocci. The 
purpose of this study is to evaluate the activity of 
classical and new fluoroquinolones against clinical 
isolates of Enterococcns spp. 
For this study, 100 consecutively collected clinical 
isolates of Enterococcus faecalis (50) and E. faclcium (50) 
were obtained from blood cultures (54), urine samples 
(32) and other clinical specimens (14) from different 
patients in the University Hospital of Seville during 
1995 and 1996. All strains were identified by both 
standard methods [4] and the API 20 STREP 
(BioMbrieux; France). 
The minimum inhibitory concentrations (MICs) 
of norfloxacin (Sigma, USA), ciprofloxacin (Bayer, 
Germany), sparfloxacin (Sigma, USA), ofloxacin 
(Hoechst, Germany), levofloxacin (Roussel, France), 
pefloxacin (Rhone-Poulenc, France), trovafloxacin 
(Pfizer, USA), clinafloxacin (Parke-Davis, USA) and 
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sparfloxacin (Rhone-Poulenc, France) were deter- 
mined by microdilution following the NCCLS 
guidelines [5]. Fluoroquinolones were tested in the 
range 64-0.03 mg/L. E. faecalis ATCC 29212 and 
Staphylococcus aureus ATCC 29213 were used as control 
strains. 
The activities of fluoroquinolones against E.faecalis 
are shown in Table 1. Susceptibility and resistance 
to ciprofloxacin were considered according to the 
NCCLS guidelines [ 5 ]  . For ciprofloxacin-susceptible 
strains, the activities of levofloxacin and trovafloxacin 
were similar to that of ciprofloxacin. The MICsUs of 
sparfloxacin and clinafloxacin, however, were four 
and eight times lower, respectively, than those of 
ciprofloxacin. Against ciprofloxacin-resistant strains, 
only clinafloxacin was more active than ciprofloxacin, 
yielding an MICyo value of 4 mg/L. In fact, if, for 
purposed of comparison, a breakpoint of 1 pg/mL (as 
defined for ciprofloxacin [5]) is used, 28.6% of these 
isolates were susceptible to clinafloxacin. 
Table 1 Activity of eight fluoroquinolones against Enterocows faecalis: MICs in pg/mL 
MICso MICro Range 
Ciprofloxacin-susceptible (YL ~ 2 2 )  
Ciprofloxacin 
Norfloxacin 
Ofloxacin 
Levofloxacin 
Pefloxacin 
Trovafloxacin 
Sparfloxacin 
Clinafloxacin 
0.5 
2 
1 
0.5 
2 
0.5 
0.125 
50.06 
1 
4 
2 
1 
4 
1 
0.25 
0.125 
50.06-1 
0.25-32 
0.25-2 
50.06-2 
0.25-16 
20.06-2 
10.06-1 
50.06-0.25 
Ciprofloxacin-resistant (n=28) 
Ciprofloxacin 64 >64 8 to >64 
Norfloxacin >64 >64 32 to >64 
Ofloxacin >64 >64 16 to >64 
Levofloxacin >64 >64 16 to >64 
Pefloxacin >64 >64 32 to >64 
Trovafloxacin >64 264 4 to >64 
Spadloxacin 64 264 2 to >64 
Clinafloxacin 4 4 0.5-4 
Table 2 Activity of eight fluoroquinolones against Enttrrococcusfaeciurn: MICs in pg/mL 
Ciprofloxacin-susceptible (n=17) 
Ciprofloxacin 
Norfloxacin 
Ofloxacin 
Levofloxacin 
Pefloxacin 
Trovafloxacin 
Sparfloxacin 
Clinafloxacin 
Ciprofloxacin-resistant (n=33) 
Ciprofloxacin 
Nortloxacin 
Ofloxacin 
Levofloxacin 
Pefloxacin 
Trovafloxacin 
Spadloxacin 
Clinafloxacin 
0.5 
2 
2 
1 
4 
0.5 
0.25 
10.06 
4 
32 
16 
8 
64 
8 
4 
1 
1 
4 
4 
2 
16 
1 
0.5 
0.25 
> 64 
> 64 
64 
32 
> 64 
16 
32 
4 
50.06-1 
1-32 
0.5-16 
1-4 
2-16 
0.125-16 
10.06-0.5 
10.06-0.5 
2 to >64 
2 to 2.64 
2 to >64 
1 to >64 
4 to >64 
0.25 to 32 
0.125 to >64 
0.125 to >64 
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Sparfloxacin and clinafloxacin were the most active 
agents against ciprofloxacin-susceptible E. faecium strains 
(Table 2) .  Pefloxacin, however, was the least active 
agent, yielding an MIC230 value of 16 nig/L. If, again, 
a breakpoint of 1 mg/L is applied, none of the strains 
was susceptible to pefloxacin. Norfloxacin and ofloxacin 
also showed very low activity against these strains. For 
ciprofloxacin-resistant E. faecium strains. all the quino- 
lones showed MIC5o values lower than those observed 
against ciprofloxacin-resistant E.faecu1is strains. In terms 
of MIC90 clinafloxacin was again the most active 
fluoroquinolone against ciprofloxacin-resistant E.jhecium 
strains, 42% and 51% of these strains were inhibited by 
1 mg/L of sparfloxacin and clinafloxacin, respectively. 
The high in vitro activity of clinafloxacin against 
enterococci has been described [6,7]. Nevertheless, the 
MICso values obtained in this study are greater than 
those obtained in previous studies, suggesting a slow 
decrease in the susceptibility of enterococci to this 
agent. The other new quinolones, levofloxacin, spar- 
floxacin and trovafloxacin, did not improve on the 
results obtained with clinafloxacin. 
In summary, clinafloxacin, and to a lesser extent 
sparfloxacin, levofloxacin and trovafloxacin, showed 
greater in vitro activity than the classical fluoro- 
quinolones against enterococci. Taking into account 
the few therapeutic alternatives for infections caused by 
rnultiresistant strains, further experimental studies will 
be needed to determine if these new fluoroquinolones 
will be useful in the treatment of serious enterococcal 
infections caused by strains resistant to other antibiotics. 
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Usefulness of delayed hypersensitivity skin tests in 
HIV infected patients 
Clin Microbiol Infecf 1997; 3: 499-500 
The demands on the health services by patients infected 
with type 1 human immunodeficiency virus (HIV-1) 
are increasing markedly. In Spain, past or present 
intravenous drug users account for a significant pro- 
portion of the total infected individuals [I]. Their visits 
to doctors are random and do not fit into defined 
patterns. 
In this context, it is extremely important to obtain 
objective data which may help in the evaluation of 
their serologic, diagnostic and clinical status. Delayed 
hypersensitivity skin tests provide a very important 
diagnostic tool for assessing cellular immunity and 
several authors have advocated their use in clinical 
practice at  the initial evaluation [2,3]. At the same time, 
lymphocyte CD4 counts have become widely accepted 
as an indicator when assigning a prophylactic or thera- 
peutic regimen and in establishing life-expectancy 
[4,5]. This indicator has gained universal currency with 
the publication of the latest C D C  criteria for staging 
and clinical categorization [6].  
The objective of the present work is to evaluate the 
response to a skin test consisting of five bacterial and 
two fungal antigens (Ag) in a sample of HIV-1 infected 
individuals at their first visit to the doctor and to 
establish its relation to the CD4 lymphocyte count. 
Between October 1985 and March 1993 we studied 
a total of 503 individuals with risk factors who presented 
for clinical evaluation at the University Clinical Hospital 
of Valladolid. Their average age was 29 k 7 years (range: 
